Who NAD+ Therapy Is Actually For (And Who Should Skip It)

Not every patient asking about NAD+ should be on it. The marketing for the category implies near-universal candidacy, which is not how a licensed clinician actually evaluates patients. The honest version is that NAD+ therapy candidates fall into a defined set of clinical profiles, and patients outside those profiles are either not yet at the point where the protocol is the right input or are in a clinical context where it should be deferred. This article walks through who fits and who does not, with the candor a patient deserves before they start spending money on a multi-month protocol.

The framing matters because the protocol is not free, the molecule is not magic, and the right answer for any given patient depends on what their clinical picture actually looks like. A clinician evaluating a candidate is asking a specific question: is this patient's profile one where prescribed subcutaneous NAD+ is likely to produce measurable benefit at the doses and cadence that prescribed NAD+ for fatigue or recovery typically uses? The answer is sometimes yes, sometimes not yet, and sometimes no.

The mid-life energy decline profile

The most common candidate is a patient in their forties or beyond reporting persistent low-level fatigue that does not resolve with sleep, is not explained by thyroid or anemia or other readily testable conditions, and is genuinely affecting their daily function. The clinical signature is recognizable: a patient who used to have stable energy across the day and now feels their afternoon collapse, whose recovery from exercise has slowed, whose sleep has become less restorative, and who has tried the standard inputs — better sleep, more protein, less alcohol, more exercise — without recovering their baseline.

This profile aligns closely with the mechanism. Tissue NAD+ declines roughly 50% by the fifth decade in most peer-reviewed assays, the salvage pathway becomes less efficient, and CD38-mediated consumption rises with age. The clinical picture the patient describes is the lived experience of those biochemical changes. A clinically supervised NAD+ protocol delivers a measurable input on the underlying chemistry, and a meaningful fraction of patients in this profile report subjective and objective response within the first eight to twelve weeks.

The clinician confirms candidacy by ruling out other causes — thyroid panel, basic metabolic panel, sleep history, medication review — and then recommends a conservative starting dose with a defined response window. If the patient does not respond by twelve weeks at adequate dose, the clinician revisits whether the protocol is the right input.

The recovery athlete

The second common candidate profile is the serious recreational or competitive athlete whose training volume has outpaced their recovery capacity. The clinical picture differs from the mid-life energy patient: this person trains hard, knows their baseline well, and has noticed a specific shift — sessions that used to leave them tired now leave them sore for 48 hours, adaptations that used to come quickly now plateau, and morning resting heart rate has drifted up across a training block that should have produced the opposite.

This profile fits NAD+ because the underlying biology is similar to age-related decline operating on a faster timescale. Heavy training raises oxidative stress, increases DNA damage from contractile stress, activates PARP enzymes, and consumes NAD+ at higher rates. If recovery infrastructure cannot keep pace, the effective NAD+ pool drops and recovery slows.

A licensed NAD+ for longevity or recovery protocol can support this profile by adding to the available pool while the athlete adjusts training load and recovery practices. The clinician evaluates the athlete's sport, training cycle, and any anti-doping considerations, and recommends a dose and cadence that matches the demand. NAD+ is not on the WADA prohibited list, but the specific compounded preparation and any concurrent peptides are reviewed individually.

The longevity-focused patient

The third candidate profile is the patient whose primary motivation is not symptomatic relief but proactive maintenance — the patient who tracks their biomarkers, follows the longevity literature, and wants a clinically supervised input on mitochondrial function rather than a self-directed supplement experiment. This patient is often asymptomatic or has mild complaints, is well-informed about the evidence base, and understands that the protocol is not a cure for aging but a defensible intervention with a real mechanism and a growing evidence footprint.

The clinical fit for this profile is good, but the conversation is different from the symptomatic patient. The clinician is more likely to recommend a moderate, sustained protocol rather than a high-dose response trial, more likely to discuss how to integrate NAD+ with the patient's other inputs (sleep, training, nutrition, peptide stack), and more likely to set expectations carefully about what the protocol can and cannot deliver.

The longevity patient who comes in expecting a measurable change in pace of aging will be disappointed; that is not what current evidence supports. The longevity patient who comes in expecting better recovery, more stable energy, and a defensible mitochondrial input is well-aligned with what the protocol actually does.

Patients who should not start

Several scenarios warrant deferral or full avoidance.

Patients in active cancer treatment should not initiate NAD+ outside of oncology-supervised protocols. The molecule supports cellular energy in healthy tissue and malignant tissue alike, and the prudent default is to avoid adding it during active disease unless the oncology team specifically recommends it.

Patients with significant cardiovascular instability — recent infarction, uncontrolled arrhythmia, severe cardiomyopathy, or unstable angina — should defer pending cardiology clearance. The vasodilatory effects of higher-dose NAD+ are minor in most patients but can be relevant in patients whose cardiovascular status is already fragile.

Pregnant or actively breastfeeding patients are contraindicated because controlled safety data does not exist in these populations.

Patients whose primary complaint is psychiatric — depression, anxiety, bipolar disorder — should pursue established psychiatric treatment first. NAD+ is sometimes mentioned in adjacent contexts in the longevity press, but it is not a substitute for psychiatric care, and a patient seeking it as such will be both poorly served clinically and likely disappointed in the response.

Patients seeking outcomes the molecule cannot deliver are not a clinical contraindication but they are a fit problem. A patient who comes to a NAD+ consultation expecting the protocol to reverse twenty years of accumulated aging will walk out either over-promised and later disappointed, or correctly informed by the clinician and unwilling to continue. Either outcome is a poor fit.

The intake and consultation process

Patients who do fit a candidate profile move through a defined intake. The first step is a clinical questionnaire covering medical history, current medications, training and lifestyle, sleep and energy patterns, prior peptide or supplement experience, and any specific symptoms or goals. The questionnaire is reviewed by a licensed clinician.

The clinician may request labs based on the clinical picture — typically a metabolic panel, thyroid function, complete blood count, and any specific markers relevant to the patient's complaints. The lab work is interpreted in the context of the patient's history rather than against population reference ranges in isolation.

A video consultation follows. The clinician confirms the clinical picture, discusses goals, reviews any questions the patient has about the protocol, and determines whether NAD+ is appropriate, what route and cadence to use, and what dose to start at. If the patient is not a good candidate, the consultation closes there; the patient does not proceed to a prescription that would not serve them.

If the protocol is appropriate, the prescription is sent to the partnered licensed 503A pharmacy. The patient receives the medication along with injection technique guidance and a defined check-in schedule. The first four to eight weeks include closer clinician contact to confirm tolerability and titrate dose if needed. The clinician schedules a formal review at twelve weeks to evaluate response and determine whether to continue, adjust, or discontinue.

Setting expectations honestly

A patient on a clinically supervised NAD+ protocol should expect the following: a real but measured improvement in energy and recovery if they are in a candidate profile, modest changes that build over weeks rather than days, side effects that are manageable and decrease over time, and a clinician who is willing to discontinue the protocol if it is not working rather than continuing to bill them indefinitely.

A patient should not expect: dramatic anti-aging outcomes, instant transformation, the molecule to substitute for inadequate sleep or training, or a protocol that runs without monitoring. The category attracts marketing claims that overstate what the evidence supports. The clinician's job is to keep the protocol calibrated against what the molecule actually does.

How TelePeptide handles candidacy

Eligibility is determined individually by a licensed clinician based on history, goals, and labs. Patients who do not fit a candidate profile are told so and not prescribed; the program does not run through to a prescription regardless of clinical picture. Telehealth NAD+ protocols on the platform default to subcutaneous home dosing with a structured check-in schedule. Compounded preparations are sourced from licensed 503A pharmacies. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved. The program is built for patients who want a clinically supervised mitochondrial input, not for patients shopping for a quick longevity fix.